Literature DB >> 7085856

A case-comparison study of hypertension and hyperparathyroidism.

J C Nainby-Luxmoore, H G Langford, N C Nelson, R L Watson, T Y Barnes.   

Abstract

The frequency of hypertension in patients with primary hyperparathyroidism has been compared with that found in cases matched for conditions of comparable surgical magnitude, age, race, sex, and days in the hospital. The mean blood pressure of the patients was 143/89 mm Hg, significantly higher than that of controls, which was 130/81 mm Hg (P less than 0.001 for systolic and diastolic pressures). The difference was especially notable in view of the fact that the mean weight of the controls was 169 lb compared to 153.9 lb for the patients. Actual hypertension, defined as a diastolic blood pressure of 90 mm Hg or more and or treatment with hypertensive therapy was much more frequent in the patients (90 of 124; 73%) than in the controls (53 of 124; 43%; P less than 0.001). Serum creatinine was 1.3 mm/dl in patients and 1.1 mm/dl in controls. The blood pressure difference between patients and controls persisted when patients with creatinine levels of 2.0 mm/dl or less were omitted. The blood pressure difference between patients and controls had disappeared by the end of hospitalization. We conclude that primary hyperparathyroidism is associated with modest blood pressure elevation, that renal damage is probably not the mechanism, and that surgical cure perhaps may lower blood pressure. The mean effect of primary hyperparathyroidism is to shift the blood pressure distribution curve to the right by approximately 15/10 mm Hg.

Entities:  

Mesh:

Year:  1982        PMID: 7085856     DOI: 10.1210/jcem-55-2-303

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Vitamin D, parathyroid hormone, and cardiovascular events among older adults.

Authors:  Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

2.  Parathyroid hypertension.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-26

3.  Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism.

Authors:  R Pacifici; H M Perry; W Shieber; E Biglieri; D M Droke; L V Avioli
Journal:  Calcif Tissue Int       Date:  1987-09       Impact factor: 4.333

4.  Cardiac structure and diastolic function in mild primary hyperparathyroidism.

Authors:  M D Walker; J B Fleischer; M R Di Tullio; S Homma; T Rundek; E M Stein; C Zhang; T Taggart; D J McMahon; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2010-03-12       Impact factor: 5.958

5.  Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism.

Authors:  Aliya Heyliger; Vin Tangpricha; Collin Weber; Jyotirmay Sharma
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

Review 6.  Derangement of glucose metabolism in hyperparathyroidism.

Authors:  M Procopio; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

Review 7.  Cardiovascular aspects of primary hyperparathyroidism.

Authors:  M D Walker; S J Silverberg
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

Review 8.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

9.  Primary hyperparathyroidism and the heart: cardiac abnormalities correlated to clinical and biochemical data.

Authors:  F Längle; C Abela; J Koller-Strametz; M Mittelböck; J Bergler-Klein; T Stefenelli; W Woloszczuk; B Niederle
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

10.  Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure.

Authors:  J A Rodríguez-Portales; C Fardella
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.